VC
DICE

Vivo Capital’s DICE Therapeutics, Inc. Common Stock DICE Stock Holding History

Vivo Capital’s Portfolio DICE Stock Details DICE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-163,136
Closed -$3.12M – 54
2022
Q1 		$3.12M Sell
163,136
-163,136
-50% -$2.91M 0.21% 45
2021
Q4 		$8.26M Sell
326,272
-83,728
-20% -$2.45M 0.5% 39
2021
Q3 		$13.4M Buy
+410,000
New +$14M 0.6% 30

Other funds holding DICE

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
NV
Northpond Ventures Bethesda, Maryland $43.7M AUM 27.27% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Vivo Capital's DICE Position: Q2 2022 in Review

Vivo Capital sold out of DICE Therapeutics, Inc. Common Stock (DICE) in Q2 2022, closing a stake of 163,136 shares — an estimated $3.12M sold.

Vivo Capital first reported a position in DICE in Q3 2021 and held it in 3 quarters. The position peaked at $13.4M in Q3 2021. 80 funds tracked by Wall St. Rank hold DICE as of Q2 2022.

  • Vivo Capital reported no remaining DICE Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Vivo Capital sold 163,136 DICE Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $3.12M.
  • Vivo Capital first reported a position in DICE Therapeutics, Inc. Common Stock in Q3 2021 and held it in 3 quarters.
  • Vivo Capital's DICE Therapeutics, Inc. Common Stock position peaked at $13.4M in Q3 2021.
  • 80 funds tracked by Wall St. Rank held DICE Therapeutics, Inc. Common Stock as of Q2 2022.

Based on Vivo Capital's 13F filing for Q2 2022, filed 15 Aug 2022.